Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Publication in The Lancet is announced of phase III bimekizumab trials in moderate to severe hidradenitis suppurativa – UCB

Written by | 25 May 2024

UCB, announced that The Lancet has published results from the Phase III BE HEARD I and BE HEARD II trials evaluating the efficacy and safety of bimekizumab, an… read more.

Almost half of patients with skin disease suffer from sleep disturbances, global study finds

Written by | 18 Oct 2023

Almost half (42%) of patients with skin disease experience sleep disturbances, a major study presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2023 has… read more.

European Commission approval for Cosentyx as first and only IL-17A inhibitor for hidradenitis suppurativa – Novartis

Written by | 14 Jun 2023

Novartis announced that the European Commission (EC) has approved Cosentyx (secukinumab) for use in adults with active moderate to severe hidradenitis suppurativa (HS) and an inadequate response to… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.